Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.jaut.2022.102959
DC FieldValue
dc.titlePost-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING)
dc.contributor.authorMa, Margaret
dc.contributor.authorSantosa, Amelia
dc.contributor.authorKong, Kok Ooi
dc.contributor.authorXu, Chuanhui
dc.contributor.authorTeng, Gim Gee
dc.contributor.authorTang, Johnston GX
dc.contributor.authorMak, Anselm
dc.contributor.authorTay, Frank
dc.contributor.authorNg, Victoria WW
dc.contributor.authorKoh, Joshua ZE
dc.contributor.authorFong, Warren
dc.contributor.authorChew, Li-Ching
dc.contributor.authorLow, Andrea
dc.contributor.authorLaw, Annie
dc.contributor.authorPoh, Yih Jia
dc.contributor.authorYeo, Siaw Ing
dc.contributor.authorLeung, Ying Ying
dc.contributor.authorGoh, Wei-Rui
dc.contributor.authorRoslan, Nur Emilia
dc.contributor.authorChuah, Tyng Yu
dc.contributor.authorAngkodjojo, Stanley
dc.contributor.authorArkachaisri, Thaschawee
dc.contributor.authorTeh, Kai Liang
dc.contributor.authorPhang, Kee Fong
dc.contributor.authorSriranganathan, Melonie
dc.contributor.authorTan, Teck Choon
dc.contributor.authorCheung, Peter
dc.contributor.authorLahiri, Manjari
dc.date.accessioned2023-10-27T06:45:39Z
dc.date.available2023-10-27T06:45:39Z
dc.date.issued2022-09
dc.identifier.citationMa, Margaret, Santosa, Amelia, Kong, Kok Ooi, Xu, Chuanhui, Teng, Gim Gee, Tang, Johnston GX, Mak, Anselm, Tay, Frank, Ng, Victoria WW, Koh, Joshua ZE, Fong, Warren, Chew, Li-Ching, Low, Andrea, Law, Annie, Poh, Yih Jia, Yeo, Siaw Ing, Leung, Ying Ying, Goh, Wei-Rui, Roslan, Nur Emilia, Chuah, Tyng Yu, Angkodjojo, Stanley, Arkachaisri, Thaschawee, Teh, Kai Liang, Phang, Kee Fong, Sriranganathan, Melonie, Tan, Teck Choon, Cheung, Peter, Lahiri, Manjari (2022-09). Post-mRNA Vaccine Flares in Autoimmune Inflammatory Rheumatic Diseases: Results from the COronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING). ARTHRITIS & RHEUMATOLOGY 74 : 1577-1579. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jaut.2022.102959
dc.identifier.issn2326-5191
dc.identifier.issn2326-5205
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/245589
dc.description.abstractBackground: Studies of flares of autoimmune inflammatory rheumatic diseases (AIIRD) after COVID-19 mRNA vaccination are limited by small sample size, short follow up or at risk of selection bias. Methods: A national retrospective cohort study of consecutive AIIRD patients ≥12 years old, across 8 hospitals who received at least one dose of a COVID-19 mRNA vaccine. Patients were included from the date of 1st vaccine dose and censored at the time of flare or on the date of the clinic visit at least 3 months from cohort entry, whichever came first. Predictors of flare were determined by Cox proportional hazards analysis. Findings: 4627 patients (73% Chinese, 71% female) of median (IQR) age 61 (48, 70) years were included; 42% Rheumatoid arthritis, 14% Systemic lupus erythematosus and 11% Psoriatic arthritis. 47% were in remission, 41% low disease activity, 10% moderate disease activity and 1% in high disease activity. 18% patients flared, of which 11.7% were within the 3-month period of interest. 11.8% patients improved. Median (IQR) time-to-flare was 60 (30, 114) days. 25% flares were self-limiting, 61% mild-moderate and 14% severe. Older patients (53–65 years and >66 years) had a lower risk of flare [HR 0.6 (95% CI 0.5–0.8) and 0.7 (0.6–0.8) respectively]. Patients with inflammatory arthritis and with active disease had a higher risk of flare [HR 1.5 (1.2–2.0) and 1.4 (1.2–1.6), respectively]. Treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), immunosuppression and prednisolone was also associated with an increased risk of flare [HR 1.5 (1.1–2), 1.2 (1.1–1.4) and 1.5 (1.2–1.8) for prednisolone ≤7.5 mg respectively]. Interpretation: There was a moderately high rate of AIIRD flares after mRNA vaccination but also improvement in several patients. Severe flares and hospitalisation were rare. Thus, vaccination remains safe and highly recommended.
dc.language.isoen
dc.publisherWILEY
dc.sourceElements
dc.subjectAutoimmune inflammatory rheumatic diseases
dc.subjectCOVID vaccines
dc.subjectRegistry
dc.typeArticle
dc.date.updated2023-10-26T03:04:57Z
dc.contributor.departmentMEDICINE
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1016/j.jaut.2022.102959
dc.description.sourcetitleARTHRITIS & RHEUMATOLOGY
dc.description.volume74
dc.description.page1577-1579
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
CONVINSING_JAutoimmunity.pdfPublished version1.33 MBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.